Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 127

Results For "CAS"

1859 News Found

Modi Inaugurates hospital complex and CoE in South Gujarat
Public Health | June 11, 2022

Modi Inaugurates hospital complex and CoE in South Gujarat

Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools


TaCa Healthcare expands its operations to Telangana and Andhra Pradesh
Healthcare | June 11, 2022

TaCa Healthcare expands its operations to Telangana and Andhra Pradesh

Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states


Takeda’s dengue vaccine candidate offers protection against dengue fever in clinical trial
Clinical Trials | June 11, 2022

Takeda’s dengue vaccine candidate offers protection against dengue fever in clinical trial

TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union


Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies
News | June 10, 2022

Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies

During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.


India's bio-economy has grown 8 times in the last 8 years: PM Modi
Biotech | June 10, 2022

India's bio-economy has grown 8 times in the last 8 years: PM Modi

We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”


National Ayurveda Research Institute for Panchakarma bags NABL Accreditation
News | June 09, 2022

National Ayurveda Research Institute for Panchakarma bags NABL Accreditation

A big boost to healthcare efforts of Ayush through NARIP, CCRAS


Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis
Drug Approval | June 09, 2022

Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis

TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.


India is dedicated to ensure health Security for every citizen: Mandaviya
Policy | June 08, 2022

India is dedicated to ensure health Security for every citizen: Mandaviya

States have an important role in ensuring food safety and healthy food practices.


MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib
News | June 07, 2022

MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib

he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients


ANI Pharmaceuticals consolidates operation post Novitium acquisition
News | June 06, 2022

ANI Pharmaceuticals consolidates operation post Novitium acquisition

Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023